- Home
- AGMH vs CMMB Comparison
AGMH vs CMMB Comparison
Compare AGMH & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGMH
- CMMB
- Stock Information
- Founded
- AGMH 2015
- CMMB 2004
- Country
- AGMH Hong Kong
- CMMB Israel
- Employees
- AGMH N/A
- CMMB N/A
- Industry
- AGMH EDP Services
- CMMB Biotechnology: Pharmaceutical Preparations
- Sector
- AGMH Technology
- CMMB Health Care
- Exchange
- AGMH Nasdaq
- CMMB Nasdaq
- Market Cap
- AGMH 17.1M
- CMMB 13.7M
- IPO Year
- AGMH 2018
- CMMB N/A
- Fundamental
- Price
- AGMH $6.87
- CMMB $3.09
- Analyst Decision
- AGMH
- CMMB Strong Buy
- Analyst Count
- AGMH 0
- CMMB 2
- Target Price
- AGMH N/A
- CMMB $26.50
- AVG Volume (30 Days)
- AGMH 12.0M
- CMMB 128.7K
- Earning Date
- AGMH 11-18-2025
- CMMB 11-13-2025
- Dividend Yield
- AGMH N/A
- CMMB N/A
- EPS Growth
- AGMH N/A
- CMMB N/A
- EPS
- AGMH 6.43
- CMMB N/A
- Revenue
- AGMH $32,044,575.00
- CMMB N/A
- Revenue This Year
- AGMH N/A
- CMMB N/A
- Revenue Next Year
- AGMH N/A
- CMMB N/A
- P/E Ratio
- AGMH $1.11
- CMMB N/A
- Revenue Growth
- AGMH N/A
- CMMB N/A
- 52 Week Low
- AGMH $1.09
- CMMB $2.39
- 52 Week High
- AGMH $107.50
- CMMB $9.84
- Technical
- Relative Strength Index (RSI)
- AGMH 56.76
- CMMB 69.21
- Support Level
- AGMH $7.59
- CMMB $2.60
- Resistance Level
- AGMH $9.49
- CMMB $2.79
- Average True Range (ATR)
- AGMH 1.98
- CMMB 0.17
- MACD
- AGMH -0.07
- CMMB -0.02
- Stochastic Oscillator
- AGMH 28.82
- CMMB 72.65
About AGMH AGM Group Holdings Inc.
AGM Group Holdings Inc is an integrated technology company. The company focuses on blockchain-oriented ASIC chip design, high-end crypto miner production, and fintech technology software services. The company generates maximum revenue from the sale of cryptocurrency mining machines and standardized computing equipment.
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.